Mr. Doan Tan Buu – Vice Chairman of the People's Committee of Dong Thap Province, gave a speech at the meeting
After being postponed for a month due to the COVID-19 pandemic, the 2020 Annual General Meeting of Shareholders was held with meticulous preparation, from health checks to the setup of the meeting space. Shareholders were seated with proper distancing, and the hall was arranged to be more ventilated. Despite the inconveniences faced by attendees during this special time, the professionalism, thoroughness, and transparency in organizing the event were highly appreciated by shareholders and investors.
At the end of 2019 and the beginning of 2020, the world suffered tremendous economic losses due to the COVID-19 pandemic, and Vietnam was no exception. However, the General Meeting still unanimously approved the Board of Directors' proposed revenue target of VND1,750 billion for 2020, with a growth rate of 23.2%. This will likely pose a major challenge for the Executive Board and all employees of Imexpharm. Nevertheless, with development potential and the determination of the entire leadership team and employees, Imexpharm is confident it will achieve this goal as expected by its shareholders and investors.
Over the past year, Imexpharm has made remarkable strides in production, business operations, investment, and corporate governance. Key achievements include the completion of the High-Tech Pharmaceutical Factory, which has already secured WHO-GMP certification and is on track to receive EU-GMP approval later this year. Additionally, the company broke ground on a herbal medicine factory and a testing center in Dong Thap. Notably, in 2019, Imexpharm was recognized for the second consecutive year as one of the Top 5 Companies with the Best Corporate Governance in the mid-cap category on the Vietnamese stock market.
At the meeting, Imexpharm received encouragement and positive feedback from the Vice Chairman of the Provincial People's Committee and the leadership of the Department of Health. The provincial leaders recognized Imexpharm's positive contributions to the sustainable development of the province, from its efforts in educational promotion and social welfare to its active support in the fight against the pandemic.
The 2020 Annual General Meeting of Shareholders concluded successfully, with 10 proposals receiving 100% approval, 1 proposal receiving 99.99%, and 2 proposals receiving 99.98% of the votes in favor.
The minutes of the meeting and the resolutions passed by the General Meeting of Shareholders can be accessed at the following link:
IMP: CBTT Biên bản và Nghị quyết cuộc họp ĐHĐCĐ 2020 (IMP: CBTT Minutes and Resolutions of the 2020 AGM)
The strategic directions approved at the 2020 General Meeting of Shareholders helped lay a solid foundation for Imexpharm’s next phase of development. This consistent spirit continued at the 2022 Annual General Meeting, where numerous notable achievements in management and sustainable growth were recognized.